Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 6/20 | 0.52 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.49 |
| ▸ | CDK1 | P06493 | 3/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.49 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.49 |
| ▸ | RET | P07949 | 2/20 | 0.49 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.48 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.46 |
| ▸ | PIM1 | P11309 | 4/20 | 0.46 |
| ▸ | PRKACA | P17612 | 4/20 | 0.46 |
| ▸ | GSK3B | P49841 | 4/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.46 |
| ▸ | CDK9 | P50750 | 4/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.46 |
| ▸ | CDK2 | P24941 | 3/20 | 0.46 |
| ▸ | HIPK2 | Q9H2X6 | 3/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13302379 | 0.79 | MAPT (0.51) | CCNB2CDK1CCNB1CCNB3PIM1 | |
| SCHEMBL13302165 | 0.78 | DYRK1A (0.56) | CDC7CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL857148 | 0.75 | TGFBR1 (0.57) | CDC7CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL16720296 | 0.75 | CDC7 (0.48) | CDC7CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL3339744 | 0.74 | BRD4 (0.67) | CDC7CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL13302381 | 0.74 | MAPT (0.44) | — | |
| SCHEMBL5618155 | 0.74 | TGFBR1 (0.71) | CDC7IKBKETBK1DYRK1AMAP4K4 | |
| SCHEMBL15397129 | 0.72 | IKBKE (0.78) | CDC7CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL918396 | 0.72 | TRPM4 (0.60) | — | |
| SCHEMBL29381319 | 0.72 | TRPM4 (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362066-B2 | Compounds and methods for treating protein folding disorders | TREVENTIS CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | SNCA, MAPT, APP | CDC7 4660/4885CCNB2 4750/4885CDK1 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.